x
CME-Tagline

Novel Approaches to Treating CMV Infection in People Receiving Solid Organ or Hematopoietic Stem Cell Transplantations

CMEO Snack

Premiere Date: Wednesday, May 11, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, May 11, 2023

Faculty


Roy F. Chemaly, MD, MPH, FIDSA, FACP Roy F. Chemaly, MD, MPH, FIDSA, FACP (Moderator)
Professor of Medicine
Chief, Infection Control Officer
Director, Clinical Virology Research
Department of Infectious Diseases, Infection Control, and Employee Health
The University of Texas MD Anderson Cancer Center
Houston, TX

Genovefa Papanicolaou, MD, FIDSA Genovefa Papanicolaou, MD, FIDSA 
Attending Physician, Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medical, Cornell University
New York, NY

Statement of Need

Cytomegalovirus (CMV) disease causes significant morbidity and mortality in patients receiving solid organ or hematopoietic stem cell transplants (SOT and HSCT, respectively). If left uncontrolled, CMV can result in high viral loads and end organ damage (EOD) in immunocompromised people. Active CMV infections are associated with additional potentially life-threatening complications, such as venous thrombosis, pneumonitis, and colitis.

It is imperative that clinicians are aware of recently approved treatment options for CMV disease. Additionally, clinicians must also be able to individualize CMV treatment to each patient as well as differentiate the benefits of monotherapy versus combination therapy.

In this CMEO Snack, join expert faculty as they discuss best strategies to identify risk factors of CMV infection, recognize the impact of CMV on treatment outcomes, and ultimately develop balanced treatment plans for patients with CMV disease.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Identify factors that increase the risk of CMV infection.
  • Recognize the impact of CMV infection on treatment outcomes for transplant recipients.
  • Develop balanced treatment plans for patients with CMV disease.

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in transplants, infectious disease, internal medicine, and/or primary care

Credit Information


ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Chemaly reports the following financial relationships:

Advisory Board: ADMA Biologics, Inc.; Janssen Pharmaceuticals, Inc.; Karius, Inc.; Partner Therapeutics, Inc.; Pulmotect, Inc.; and Shionogi Inc.

Consultant: Adagio Therapeutics, Inc.; Ansun Biopharma; Genentech, Inc.; Merck & Co., Inc.; Oxford Immunotec USA, Inc.; Qiagen; and Takeda Pharmaceuticals U.S.A., Inc./Shire Pharmaceuticals

Grants: National Institutes of Health (NIH)/National Cancer Institute (NCI) (RO1)

Research Support: AiCuris Anti-infective Cures AG; Ansun Biopharma; Chimerix; Eurofins Viracor; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Karius, Inc.; Merck & Co., Inc.; Oxford Immunotec USA, Inc.; and Takeda Pharmaceuticals U.S.A., Inc./Shire Pharmaceuticals

Dr. Papanicolaou reports the following financial relationships:

Advisory Board: Cidara Therapeutics, Inc.; CSL Behring; Merck & Co., Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Consultant: AlloVir; Amplyx Pharmaceuticals, Inc.; Octapharma USA, Inc.; and Symbio

Grants: Merck & Co., Inc.

Research Support: Merck & Co., Inc. and Takeda Pharmaceuticals U.S.A., Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships:
  • Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
  • Janan Sarwar, PharmD (planning committee)
  • David Modrak, PhD (planning committee)
  • Evan Luberger (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)


  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    This document was last modified on:

    SN-167-051122-20